**Suzhou Basecare Medical Corporation Limited**
**蘇州貝康醫療股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 2170)**

# VOLUNTARY ANNOUNCEMENT
# DA5000 HIGH-THROUGHPUT GENE SEQUENCER OBTAINING CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FROM THE NMPA

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company's DA5000 high-throughput gene sequencer obtained the Class III medical device registration certificate (registration certificate No.: Guo Xie Zhu Zhun 20243221930) from the National Medical Products Administration of China (the "**NMPA**") on September 30, 2024.

The Company's DA5000 high-throughput gene sequencer, as a latest domestic high-throughput gene sequencing platform, is a key project of the 14th Five-Year Plan for National Key Research and Development Program of China (十四五國家重點研發計劃重點專項), is specially designed for solving a number of clinical problems in reproductive medicine, and can be widely used in pre-pregnancy, prenatal, pre-implantation and neonatal genetic disease screening, covering the entire reproductive cycle, with the features of high efficiency and high precision:

(1) DA5000 high-throughput gene sequencer can provide one-stop genetic laboratory solution for assisted reproductive centers, covering the whole process from sample pre-processing to report generation, including self-developed reagents, equipment and software, which comprehensively improves the efficiency of the genetic laboratory and shortens the testing period;

(2) DA5000 high-throughput gene sequencer has strong multi-sample and multi-project parallel processing capabilities, especially suitable for reproductive genetic testing, which can significantly improve the accuracy of genetic screening, precisely detect genetic variations, and greatly reduce the risk of omitted testing and misjudgment. Compared to the previous generation medium-throughput platform DA500 (registration certificate No.: 20233221281), DA5000 high-throughput gene sequencer is capable of processing 40–50 embryo samples in a single test, with a throughput increase of more than 4 times.

The approval of DA5000 high-throughput gene sequencer further strengthens the Company's platform advantage in the overall solution for assisted reproductive genetic testing, which can fully satisfy the testing needs of reproductive genetic laboratories of all scales. Meanwhile, the accompanying automated analysis software can rapidly process and accurately interpret large-scale data, providing scientific and accurate support for clinical decision-making. As a result, the genetic laboratory solution with DA5000 high-throughput sequencer as the core greatly improves the speed, accuracy and automation of testing, and gene optimizes the whole process of genetic testing in the Center for Reproductive Medicine.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**Suzhou Basecare Medical Corporation Limited**
**Dr. Liang Bo**
*Chairman and General Manager*

Suzhou, PRC, September 30, 2024

*As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. XU Wenbo, Mr. WANG Weipeng and Mr. LING Yang as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.*